Kiora Pharmaceuticals (KPRX) Competitors $3.04 -0.05 (-1.46%) As of 01:13 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock KPRX vs. ELYM, PLUR, ACRV, SCYX, LTRN, SCLX, LVTX, COEP, MAAQ, and ALGSShould you be buying Kiora Pharmaceuticals stock or one of its competitors? The main competitors of Kiora Pharmaceuticals include Eliem Therapeutics (ELYM), Pluri (PLUR), Acrivon Therapeutics (ACRV), SCYNEXIS (SCYX), Lantern Pharma (LTRN), Scilex (SCLX), LAVA Therapeutics (LVTX), Coeptis Therapeutics (COEP), Mana Capital Acquisition (MAAQ), and Aligos Therapeutics (ALGS). These companies are all part of the "pharmaceutical products" industry. Kiora Pharmaceuticals vs. Its Competitors Eliem Therapeutics Pluri Acrivon Therapeutics SCYNEXIS Lantern Pharma Scilex LAVA Therapeutics Coeptis Therapeutics Mana Capital Acquisition Aligos Therapeutics Kiora Pharmaceuticals (NASDAQ:KPRX) and Eliem Therapeutics (NASDAQ:ELYM) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their earnings, institutional ownership, community ranking, dividends, risk, profitability, analyst recommendations, valuation and media sentiment. Do insiders & institutionals have more ownership in KPRX or ELYM? 77.0% of Kiora Pharmaceuticals shares are owned by institutional investors. Comparatively, 69.8% of Eliem Therapeutics shares are owned by institutional investors. 0.1% of Kiora Pharmaceuticals shares are owned by company insiders. Comparatively, 4.7% of Eliem Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth. Does the MarketBeat Community favor KPRX or ELYM? Kiora Pharmaceuticals received 9 more outperform votes than Eliem Therapeutics when rated by MarketBeat users. Likewise, 75.00% of users gave Kiora Pharmaceuticals an outperform vote while only 56.25% of users gave Eliem Therapeutics an outperform vote. CompanyUnderperformOutperformKiora PharmaceuticalsOutperform Votes1875.00% Underperform Votes625.00% Eliem TherapeuticsOutperform Votes956.25% Underperform Votes743.75% Which has higher earnings & valuation, KPRX or ELYM? Kiora Pharmaceuticals has higher revenue and earnings than Eliem Therapeutics. Eliem Therapeutics is trading at a lower price-to-earnings ratio than Kiora Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioKiora Pharmaceuticals$16M0.58-$12.51M-$2.90-1.05Eliem TherapeuticsN/AN/A-$35.12M-$0.53-2.42 Does the media refer more to KPRX or ELYM? In the previous week, Kiora Pharmaceuticals had 2 more articles in the media than Eliem Therapeutics. MarketBeat recorded 2 mentions for Kiora Pharmaceuticals and 0 mentions for Eliem Therapeutics. Kiora Pharmaceuticals' average media sentiment score of 0.96 beat Eliem Therapeutics' score of 0.00 indicating that Kiora Pharmaceuticals is being referred to more favorably in the media. Company Overall Sentiment Kiora Pharmaceuticals Positive Eliem Therapeutics Neutral Which has more volatility and risk, KPRX or ELYM? Kiora Pharmaceuticals has a beta of -0.68, suggesting that its share price is 168% less volatile than the S&P 500. Comparatively, Eliem Therapeutics has a beta of -0.39, suggesting that its share price is 139% less volatile than the S&P 500. Is KPRX or ELYM more profitable? Kiora Pharmaceuticals' return on equity of 21.32% beat Eliem Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Kiora PharmaceuticalsN/A 21.32% 16.39% Eliem Therapeutics N/A -47.03%-45.97% Do analysts prefer KPRX or ELYM? Kiora Pharmaceuticals currently has a consensus price target of $10.00, indicating a potential upside of 229.49%. Given Kiora Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe Kiora Pharmaceuticals is more favorable than Eliem Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Kiora Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00Eliem Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 SummaryKiora Pharmaceuticals beats Eliem Therapeutics on 13 of the 16 factors compared between the two stocks. Get Kiora Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for KPRX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding KPRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart KPRX vs. The Competition Export to ExcelMetricKiora PharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$9.24M$6.92B$5.61B$8.57BDividend YieldN/A2.54%5.28%4.17%P/E Ratio-1.058.6327.2219.81Price / Sales0.58265.57411.31154.51Price / CashN/A65.8538.3234.64Price / Book0.436.587.014.65Net Income-$12.51M$143.75M$3.23B$248.05M7 Day Performance-1.46%1.52%-0.06%-0.15%1 Month Performance-4.86%12.43%8.75%4.50%1 Year Performance-37.29%3.67%32.44%13.76% Kiora Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)KPRXKiora Pharmaceuticals3.1405 of 5 stars$3.04-1.5%$10.00+229.5%-37.4%$9.24M$16M-1.0510Short Interest ↓Gap DownELYMEliem TherapeuticsN/A$1.18-3.3%N/A-85.2%$35.11MN/A-2.239PLURPluri2.2971 of 5 stars$4.47+0.2%$12.00+168.5%-24.8%$35.01M$1.03M-0.80150Short Interest ↑ACRVAcrivon Therapeutics4.2614 of 5 stars$1.11+5.7%$17.71+1,495.9%-83.2%$34.80MN/A-0.4158News CoveragePositive NewsAnalyst RevisionHigh Trading VolumeSCYXSCYNEXIS0.871 of 5 stars$0.89+1.7%N/A-62.0%$34.71M$2.63M-1.2060Positive NewsLTRNLantern Pharma2.5709 of 5 stars$3.19+4.6%$25.00+683.7%-42.8%$34.40MN/A-1.7920Insider TradeSCLXScilex2.3881 of 5 stars$4.91-4.1%$455.00+9,166.8%-89.7%$34.13M$50.71M-5.9280Positive NewsLVTXLAVA Therapeutics2.5662 of 5 stars$1.29-1.5%$3.17+145.5%-42.8%$33.93M$4.99M-1.2560Positive NewsCOEPCoeptis Therapeutics1.3727 of 5 stars$9.30+1.6%N/A+42.8%$32.68M$62.87K-1.602Positive NewsMAAQMana Capital AcquisitionN/A$3.99-5.2%N/A+605.7%$32.42MN/A0.001ALGSAligos Therapeutics4.6311 of 5 stars$5.25-0.8%$70.00+1,233.3%-37.0%$32.10M$3.27M-0.3990News CoveragePositive NewsGap Down Related Companies and Tools Related Companies Eliem Therapeutics Competitors Pluri Competitors Acrivon Therapeutics Competitors SCYNEXIS Competitors Lantern Pharma Competitors Scilex Competitors LAVA Therapeutics Competitors Coeptis Therapeutics Competitors Mana Capital Acquisition Competitors Aligos Therapeutics Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:KPRX) was last updated on 6/13/2025 by MarketBeat.com Staff From Our PartnersYour Bank Account Is No Longer SafeWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | SponsoredUtah’s New Oil FindThe Real Reason 218,000 Acres Just Vanished The government just quietly leased 218,000 acres in the middle ...Stansberry Research | SponsoredThe End of Elon Musk…?The End of Elon Musk? Don't make him laugh. Jeff Brown has been hearing this same tired story for years, an...Brownstone Research | SponsoredWhy July 22nd Could Mean Big Changes for Social SecurityIn a stunning move, President Trump has authorized an AI-led transformation of federal agencies, including Soc...Altimetry | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredJuly 2025 Rule Change to Impact Retirement InvestorsThere's a massive change from a new rule going into effect this July. And it's one the Big Banks are alread...Premier Gold Co | SponsoredBanks aren’t ready for this altcoin—are you?Donald Trump just fast-tracked TWO major crypto bills with an August deadline! Your window of opportunity i...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Kiora Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Kiora Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy KPRX Stock Free KPRX Stock Alerts